iBio, Inc. Q2 2025: Assets $9.1M, Liabilities $1.9M
Ticker: IBIO · Form: 10-Q · Filed: 2025-02-10T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, assets, liabilities
TL;DR
iBio Q2: Assets $9.1M, Liabilities $1.9M. Still standing.
AI Summary
iBio, Inc. filed a 10-Q for the period ending December 31, 2024. The company reported total assets of $9.132 million and total liabilities of $1.856 million for the quarter. Revenue for the period was not explicitly stated, but the filing references a Purchase and Sale Agreement dated May 17, 2024, and a Stock Purchase Agreement related to Rubryc Therapeutics, Inc. from August 23, 2021.
Why It Matters
This filing provides a snapshot of iBio's financial health, including its asset and liability levels, which are crucial for investors to assess the company's stability and operational capacity.
Risk Assessment
Risk Level: medium — The filing indicates a company with significant liabilities relative to its assets, and the absence of clear revenue figures suggests potential financial challenges.
Key Numbers
- $9.132M — Total Assets (As of December 31, 2024)
- $1.856M — Total Liabilities (As of December 31, 2024)
- 2024-05-17 — Purchase and Sale Agreement Date (Key contractual event)
- 2021-08-23 — Stock Purchase Agreement Date (Related to Rubryc Therapeutics, Inc.)
Key Players & Entities
- iBio, Inc. (company) — Filer of the 10-Q
- December 31, 2024 (date) — End of the reporting period
- $9.132 million (dollar_amount) — Total assets
- $1.856 million (dollar_amount) — Total liabilities
- May 17, 2024 (date) — Date of a Purchase and Sale Agreement
- Rubryc Therapeutics, Inc. (company) — Mentioned in relation to a Stock Purchase Agreement
- August 23, 2021 (date) — Date of a Stock Purchase Agreement
FAQ
What were iBio, Inc.'s total revenues for the quarter ending December 31, 2024?
The filing does not explicitly state the total revenues for the quarter ending December 31, 2024.
What is the nature of the Purchase and Sale Agreement dated May 17, 2024?
The filing identifies the agreement as 'ibio:PurchaseAndSaleAgreementMember' but does not provide specific details on its terms or purpose.
What was the company's net income or loss for the quarter ending December 31, 2024?
The filing does not explicitly state the net income or loss for the quarter ending December 31, 2024.
What is the relationship between iBio, Inc. and Rubryc Therapeutics, Inc. as indicated by the Stock Purchase Agreement?
The filing mentions a Stock Purchase Agreement between iBio, Inc. and Rubryc Therapeutics, Inc. dated August 23, 2021, but does not detail the specifics of the transaction.
What were the company's cash and cash equivalents as of December 31, 2024?
The filing indicates cash and cash equivalents of $1.525 million as of December 31, 2024.
From the Filing
0001420720-25-000012.txt : 20250210 0001420720-25-000012.hdr.sgml : 20250210 20250210161531 ACCESSION NUMBER: 0001420720-25-000012 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250210 DATE AS OF CHANGE: 20250210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 25605927 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 10-Q 1 ibio-20241231x10q.htm 10-Q iBio, Inc._December 31, 2024 9132000 1856000 8880000 1525000 9132000 1856000 8880000 1525000 0001420720 --06-30 2025 Q2 false 1000000 0.001 0 0 0 275000000 0.001 8623676 9167670 0.48 2.42 0.94 6.27 0.00 0.00 2.00 0.00 2.88 0.48 4.42 0.94 9.15 0.05 0 0 P3Y P20Y 5000 10000 0.05 0.05 P61D 2.00 0.48 2.42 0.94 6.27 0.00 2.00 0.00 2.88 0.48 4.42 0.94 9.15 P3Y P3Y 1 1 0001420720 us-gaap:SegmentDiscontinuedOperationsMember ibio:ContractDevelopmentAndManufacturingOrganizationMember ibio:PurchaseAndSaleAgreementMember 2024-05-17 2024-05-17 0001420720 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001420720 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001420720 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001420720 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001420720 ibio:RubrycTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember ibio:StockPurchaseAgreementMember 2021-08-23 2021-08-23 0001420720 us-gaap:CommonStockMember 2023-11-29 2023-11-29 0001420720 2023-11-29 2023-11-29 0001420720 us-gaap:RetainedEarningsMember 2024-12-31 0001420720 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001420720 us-gaap:RetainedEarningsMember 2024-09-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001420720 2024-09-30 0001420720 us-gaap:RetainedEarningsMember 2024-06-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001420720 us-gaap:RetainedEarningsMember 2023-12-31 0001420720 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001420720 us-gaap:RetainedEarningsMember 2023-09-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001420720 2023-09-30 0001420720 us-gaap:RetainedEarningsMember 2023-06-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001420720 ibio:FirstInsuranceFundingMember us-gaap:NotesPayableOtherPayablesMember ibio:InsurancePremiumFinancingAgreementMember 2024-12-31 0001420720 ibio:FirstInsuranceFundingLoan2Member us-gaap:NotesPayableOtherPayablesMember ibio:InsurancePremiumFinancingAgreementMember 2024-12-31 0001420720 ibio:WoodforestNationalBankMember us-gaap:NotesPayableToBanksMember ibio:CreditAgreementWithWoodforestNationalBankMember 2024-12-31 0001420720 us-gaap:CommonStockMember 2024-12-31 0001420720 us-gaap:CommonStockMember 2024-09-30 0001420720 us-gaap:CommonStockMember 2024-06-30 0001420720 us-gaap:CommonStockMember 2023-12-31 0001420720 us-gaap:CommonStockMember 2023-09-30 0001420720 us-gaap:CommonStockMember 2023-06-30 0001420720 ibio:CompanyOfficersAndDirectorsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember ibio:SecuritiesPurchaseAgreement2025Member 2025-01-10 0001420720 ibio:WoodforestNationalBankMember ibio:PreFundedWarrantsMember us-gaap:NotesPayableToBanksMember ibio:WoodforestSettlementAgreementMember 2024-05-17 0001420720 ibio:ChardanCapitalMarketsMember ibio:PreFundedWarrantsAndSeriesEWarrantsMember us-gaap:CommonStock